[1] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, The lancet, 395 (2020) 497-506.
[2] C.I. Paules, H.D. Marston, A.S. Fauci, Coronavirus infections—more than just the common cold, Jama, 323 (2020) 707-708.
[3] F. Coperchini, L. Chiovato, L. Croce, F. Magri, M. Rotondi, The cytokine storm in COVID-19: an overview of the involvement of the chemokine/chemokine-receptor system, Cytokine & Growth Factor Reviews, (2020).
[4] K. Ratia, K.S. Saikatendu, B.D. Santarsiero, N. Barretto, S.C. Baker, R.C. Stevens, A.D. Mesecar, Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme, Proceedings of the National Academy of Sciences, 103 (2006) 5717-5722.
[5] J.M. Ferrara, S. Abhyankar, D. Gilliland, Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1, Transplantation proceedings, 1993, pp. 1216-1217.
[6] K. Yuen, S. Wong, Human infection by avian influenza A H5N1, Hong Kong Medical Journal, (2005).
[7] M.Z. Tay, C.M. Poh, L. Rénia, P.A. MacAry, L.F.P. Ng, The trinity of COVID-19: immunity, inflammation and intervention, Nature Reviews Immunology, 20 (2020) 363-374.
[8] C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, The Lancet, 395 (2020) 497-506.
[9] M. Soy, G. Keser, P. Atagunduz, F. Tabak, I. Atagündüz, S. Kayhan, Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment, Clinical Rheumatology, 39 (2020).
[10] C.C. Chow, S.S. Simons Jr, An approach to greater specificity for glucocorticoids, Frontiers in Endocrinology, 9 (2018) 76.
[11] R. Brattsand, M. Linden, Cytokine modulation by glucocorticoids: mechanisms and actions in cellular studies, Alimentary pharmacology & therapeutics, 10 (1996) 81-90.
[12] V. Sannarangappa, R. Jalleh, Inhaled corticosteroids and secondary adrenal insufficiency, The open respiratory medicine journal, 8 (2014) 93.
[13] K. Ghoreschi, A. Laurence, J.J. O’Shea, Janus kinases in immune cell signaling, Immunological reviews, 228 (2009) 273-287.
[14] C. Schindler, D.E. Levy, T. Decker, JAK-STAT signaling: from interferons to cytokines, Journal of Biological Chemistry, 282 (2007) 20059-20063.
[15] C. Ding, G. Jones, Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases, Reviews on recent clinical trials, 1 (2006) 193-200.
[16] A. Zumla, J.F. Chan, E.I. Azhar, D.S. Hui, K.Y. Yuen, Coronaviruses - drug discovery and therapeutic options, Nature reviews. Drug discovery, 15 (2016) 327-347.
[17] L. Kiemer, O. Lund, S. Brunak, N. Blom, Coronavirus 3CL pro proteinase cleavage sites: Possible relevance to SARS virus pathology, BMC bioinformatics, 5 (2004) 72.
[18] G.A. Gyebi, O.B. Ogunro, A.P. Adegunloye, O.M. Ogunyemi, S.O. Afolabi, Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CLpro): An in silico screening of alkaloids and terpenoids from African medicinal plants, Journal of Biomolecular Structure and Dynamics, (2020) 1-19.
[19] G.A. Gyebi, A.P. Adegunloye, I.M. Ibrahim, O.M. Ogunyemi, S.O. Afolabi, O.B. Ogunro, Prevention of SARS-CoV-2 cell entry: insight from in silico interaction of drug-like alkaloids with spike glycoprotein, human ACE2, and TMPRSS2, J Biomol Struct Dyn, (2020) 1-25.
[20] O.M. Ogunyemi, G.A. Gyebi, A.A. Elfiky, S.O. Afolabi, O.B. Ogunro, A.P. Adegunloye, I.M. Ibrahim, Alkaloids and flavonoids from African phytochemicals as potential inhibitors of SARS-Cov-2 RNA-dependent RNA polymerase: an in silico perspective, Antiviral Chemistry and Chemotherapy, 28 (2020) 2040206620984076.
[21] D.W. Cain, J.A. Cidlowski, After 62 years of regulating immunity, dexamethasone meets COVID-19, Nature Reviews Immunology, 20 (2020) 587-588.
[22] S.K. Patel, G. Saikumar, J. Rana, J. Dhama, M.I. Yatoo, R. Tiwari, A.J. Rodríguez-Morales, K. Dhama, Dexamethasone: A boon for critically ill COVID-19 patients?, Travel Medicine and Infectious Disease, (2020).
[23] Q.-C. Huang, M.-J. Wang, X.-M. Chen, W.-L. Yu, Y.-L. Chu, X.-H. He, R.-Y. Huang, Can active components of licorice, glycyrrhizin and glycyrrhetinic acid, lick rheumatoid arthritis?, Oncotarget, 7 (2016) 1193.
[24] R. Shah, V. Gulati, E.A. Palombo, Pharmacological properties of guggulsterones, the major active components of gum guggul, Phytotherapy research, 26 (2012) 1594-1605.
[25] S. Darshan, R. Doreswamy, Patented antiinflammatory plant drug development from traditional medicine, Phytotherapy Research: An International Journal Devoted to Pharmacological and Toxicological Evaluation of Natural Product Derivatives, 18 (2004) 343-357.
[26] S. Bale, G. Pulivendala, C. Godugu, Withaferin A attenuates bleomycin‐induced scleroderma by targeting FoxO3a and NF‐κβ signaling: Connecting fibrosis and inflammation, Biofactors, 44 (2018) 507-517.
[27] A. Haratake, D. Watase, S. Setoguchi, N. Nagata-Akaho, K. Matsunaga, J. Takata, Effect of orally ingested diosgenin into diet on skin collagen content in a low collagen skin mouse model and its mechanism of action, Life Sciences, 174 (2017) 77-82.
[28] N. Panda, S. Banerjee, N.B. Mandal, N.P. Sahu, Pregnane glycosides, Natural Product Communications, 1 (2006) 1934578X0600100813.
[29] G.A. Gyebi, J.O. Adebayo, O.E. Olorundare, A. Pardede, M. Ninomiya, A.O. Saheed, A.S. Babatunde, M. Koketsu, Iloneoside: a cytotoxic ditigloylated pregnane glycoside from the leaves of Gongronema latifolium Benth, Natural product research, 32 (2018) 2882-2886.
[30] Z.-m. Lin, Y.-t. Liu, Y.-t. Huang, X.-q. Yang, F.-h. Zhu, W. Tang, W.-m. Zhao, S.-j. He, J.-p. Zuo, Anti-nociceptive, anti-inflammatory and anti-arthritic activities of pregnane glycosides from the root bark of Periploca sepium Bunge, Journal of Ethnopharmacology, 265 (2021) 113345.
[31] J. Min, L. Perera, J.M. Krahn, C.M. Jewell, A.F. Moon, J.A. Cidlowski, L.C. Pedersen, Probing dominant negative behavior of glucocorticoid receptor β through a hybrid structural and biochemical approach, Molecular and cellular biology, 38 (2018).
[32] H.W. Ng, W. Zhang, M. Shu, H. Luo, W. Ge, R. Perkins, W. Tong, H. Hong, Competitive molecular docking approach for predicting estrogen receptor subtype α agonists and antagonists, BMC bioinformatics, BioMed Central, 2014, pp. S4.
[33] S. Dallakyan, A.J. Olson, Small-molecule library screening by docking with PyRx, Chemical biology, Springer2015, pp. 243-250.
[34] O. Trott, A.J. Olson, AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading, Journal of computational chemistry, 31 (2010) 455-461.
[35] N.M. O'Boyle, M. Banck, C.A. James, C. Morley, T. Vandermeersch, G.R. Hutchison, Open Babel: An Open chemical toolbox, Journal of cheminformatics, 3 (2011) 33-33.
[36] J.C. Phillips, R. Braun, W. Wang, J. Gumbart, E. Tajkhorshid, E. Villa, C. Chipot, R.D. Skeel, L. Kale, K.J.J.o.c.c. Schulten, Scalable molecular dynamics with NAMD, 26 (2005) 1781-1802.
[37] B.R. Brooks, C.L. Brooks III, A.D. Mackerell Jr, L. Nilsson, R.J. Petrella, B. Roux, Y. Won, G. Archontis, C. Bartels, S.J.J.o.c.c. Boresch, CHARMM: the biomolecular simulation program, 30 (2009) 1545-1614.
[38] J. Lee, X. Cheng, J.M. Swails, M.S. Yeom, P.K. Eastman, J.A. Lemkul, S. Wei, J. Buckner, J.C. Jeong, Y.J.J.o.c.t. Qi, computation, CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field, 12 (2016) 405-413.
[39] W. Humphrey, A. Dalke, K.J.J.o.m.g. Schulten, VMD: visual molecular dynamics, 14 (1996) 33-38.
[40] T. Tubiana, J.-C. Carvaillo, Y. Boulard, S.p.J.J.o.c.i. Bressanelli, modeling, TTClust: a versatile molecular simulation trajectory clustering program with graphical summaries, 58 (2018) 2178-2182.
[41] S. Salentin, S. Schreiber, V.J. Haupt, M.F. Adasme, M.J.N.a.r. Schroeder, PLIP: fully automated protein–ligand interaction profiler, 43 (2015) W443-W447.
[42] W.L. DeLano, PyMOL, 2002.
[43] A. Daina, O. Michielin, V. Zoete, SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules, Scientific reports, 7 (2017) 42717.
[44] F. Cheng, W. Li, Y. Zhou, J. Shen, Z. Wu, G. Liu, P.W. Lee, Y. Tang, admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties, Journal of chemical information and modeling, 52 (2012) 3099-3105.
[45] W. Yu, A.D. MacKerell, Computer-aided drug design methods, Antibiotics, Springer2017, pp. 85-106.
[46] L.D. Álvarez, M.A. Martí, A.S. Veleiro, D.M. Presman, D.A. Estrin, A. Pecci, G. Burton, Exploring the molecular basis of action of the passive antiglucocorticoid 21-hydroxy-6, 19-epoxyprogesterone, Journal of medicinal chemistry, 51 (2008) 1352-1360.
[47] L.D. Álvarez, M.A. Martí, A.S. Veleiro, R.I. Misico, D.A. Estrin, A. Pecci, G. Burton, Hemisuccinate of 21‐Hydroxy‐6, 19‐Epoxyprogesterone: A Tissue‐Specific Modulator of the Glucocorticoid Receptor, ChemMedChem: Chemistry Enabling Drug Discovery, 3 (2008) 1869-1877.
[48] B. Kauppi, C. Jakob, M. Färnegårdh, J. Yang, H. Ahola, M. Alarcon, K. Calles, O. Engström, J. Harlan, S. Muchmore, The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain ru-486 induces a transconformation that leads to active antagonism, Journal of Biological Chemistry, 278 (2003) 22748-22754.
[49] D. Ray, C.-S. Suen, A. Brass, J. Soden, A. White, Structure/function of the human glucocorticoid receptor: tyrosine 735 is important for transactivation, Molecular Endocrinology, 13 (1999) 1855-1863.
[50] M. Katz, E.H. Gans, Topical corticosteroids, structure-activity and the glucocorticoid receptor: discovery and development—a process of ‘‘planned serendipity’’, Journal of pharmaceutical sciences, 97 (2008) 2936-2947.
[51] S.-S. Hong, J.H. Choi, S.Y. Lee, Y.-H. Park, K.-Y. Park, J.Y. Lee, J. Kim, V. Gajulapati, J.-I. Goo, S. Singh, A novel small-molecule inhibitor targeting the IL-6 receptor β subunit, glycoprotein 130, The Journal of Immunology, 195 (2015) 237-245.
[52] Z. Wang, Y. Wang, P. Vilekar, S.-P. Yang, M. Gupta, M.I. Oh, A. Meek, L. Doyle, L. Villar, A. Brennecke, Small molecule therapeutics for COVID-19: repurposing of inhaled furosemide, PeerJ, 8 (2020) e9533.
[53] W. Somers, M. Stahl, J.S. Seehra, 1.9 Å crystal structure of interleukin 6: implications for a novel mode of receptor dimerization and signaling, The EMBO journal, 16 (1997) 989-997.
[54] R. Savino, A. Lahm, A.L. Salvati, L. Ciapponi, E. Sporeno, S. Altamura, G. Paonessa, C. Toniatti, G. Ciliberto, Generation of interleukin‐6 receptor antagonists by molecular‐modeling guided mutagenesis of residues important for gp130 activation, The EMBO journal, 13 (1994) 1357-1367.
[55] M. Ehlers, J. GRÖTZINGER, M. FISCHER, H.K. BOS, J.P. BRAKENHOFF, S. ROSE-JOHN, Identification of single amino acid residues of human IL-6 involved in receptor binding and signal initiation, Journal of interferon & cytokine research, 16 (1996) 569-576.
[56] K. Yamaoka, P. Saharinen, M. Pesu, V.E. Holt, O. Silvennoinen, J.J. O'Shea, The janus kinases (jaks), Genome biology, 5 (2004) 1-6.
[57] W. Vainchenker, S.N. Constantinescu, JAK/STAT signaling in hematological malignancies, Oncogene, 32 (2013) 2601-2613.
[58] C. Rakieh, P.G. Conaghan, Tofacitinib for treatment of rheumatoid arthritis, Advances in therapy, 30 (2013) 713-726.
[59] M.M. Vasbinder, M. Alimzhanov, M. Augustin, G. Bebernitz, K. Bell, C. Chuaqui, T. Deegan, A.D. Ferguson, K. Goodwin, D. Huszar, Identification of azabenzimidazoles as potent JAK1 selective inhibitors, Bioorganic & medicinal chemistry letters, 26 (2016) 60-67.
[60] M.L. Vazquez, N. Kaila, J.W. Strohbach, J.D. Trzupek, M.F. Brown, M.E. Flanagan, M.J. Mitton-Fry, T.A. Johnson, R.E. TenBrink, E.P. Arnold, Identification of N-{cis-3-[Methyl (7 H-pyrrolo [2, 3-d] pyrimidin-4-yl) amino] cyclobutyl} propane-1-sulfonamide (PF-04965842): A Selective JAK1 Clinical Candidate for the Treatment of Autoimmune Diseases, Journal of medicinal chemistry, 61 (2018) 1130-1152.
[61] Q. Su, E. Banks, G. Bebernitz, K. Bell, C.F. Borenstein, H. Chen, C.E. Chuaqui, N. Deng, A.D. Ferguson, S. Kawatkar, Discovery of (2 R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl) amino] pyrimidin-4-yl]-1 H-indol-7-yl]-2-(4-methylpiperazin-1-yl) propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor, Journal of medicinal chemistry, 63 (2020) 4517-4527.
[62] M. Zak, E.J. Hanan, P. Lupardus, D.G. Brown, C. Robinson, M. Siu, J.P. Lyssikatos, F.A. Romero, G. Zhao, T. Kellar, Discovery of a class of highly potent Janus kinase 1/2 (JAK1/2) inhibitors demonstrating effective cell-based blockade of IL-13 signaling, Bioorganic & medicinal chemistry letters, 29 (2019) 1522-1531.
[63] L. Zhang, D. Lin, X. Sun, U. Curth, C. Drosten, L. Sauerhering, S. Becker, K. Rox, R. Hilgenfeld, Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors, Science (New York, N.Y.), 368 (2020) 409-412.
[64] H. Yang, W. Xie, X. Xue, K. Yang, J. Ma, W. Liang, Q. Zhao, Z. Zhou, D. Pei, J. Ziebuhr, Design of wide-spectrum inhibitors targeting coronavirus main proteases, PLoS Biol, 3 (2005) e324.
[65] B.T. Freitas, I.A. Durie, J. Murray, J.E. Longo, H.C. Miller, D. Crich, R.J. Hogan, R.A. Tripp, S.D. Pegan, Characterization and noncovalent inhibition of the deubiquitinase and deISGylase activity of SARS-CoV-2 papain-like protease, ACS Infectious Diseases, (2020).
[66] Q. Li, W. Peng, Y. Ou, Prediction and analysis of key protein structures of 2019-nCoV, Future Virology, (2020).
[67] C.-Y. Chou, H.-Y. Lai, H.-Y. Chen, S.-C. Cheng, K.-W. Cheng, Y.-W. Chou, Structural basis for catalysis and ubiquitin recognition by the severe acute respiratory syndrome coronavirus papain-like protease, Acta Crystallographica Section D: Biological Crystallography, 70 (2014) 572-581.
[68] C.M. Daczkowski, J.V. Dzimianski, J.R. Clasman, O. Goodwin, A.D. Mesecar, S.D. Pegan, Structural insights into the interaction of coronavirus papain-like proteases and interferon-stimulated gene product 15 from different species, Journal of molecular biology, 429 (2017) 1661-1683.
[69] Y. Gao, L. Yan, Y. Huang, F. Liu, Y. Zhao, L. Cao, T. Wang, Q. Sun, Z. Ming, L. Zhang, Structure of the RNA-dependent RNA polymerase from COVID-19 virus, Science (New York, N.Y.), 368 (2020) 779-782.
[70] H. Schäcke, W.-D. Döcke, K. Asadullah, Mechanisms involved in the side effects of glucocorticoids, Pharmacology & therapeutics, 96 (2002) 23-43.
[71] C.A. Lipinski, Avoiding investment in doomed drugs, Curr Drug Discov, 1 (2001) 17-19.
[72] A.K. Ghose, V.N. Viswanadhan, J.J. Wendoloski, A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases, Journal of combinatorial chemistry, 1 (1999) 55-68.
[73] D.F. Veber, S.R. Johnson, H.-Y. Cheng, B.R. Smith, K.W. Ward, K.D. Kopple, Molecular properties that influence the oral bioavailability of drug candidates, Journal of medicinal chemistry, 45 (2002) 2615-2623.
[74] W.J. Egan, K.M. Merz, J.J. Baldwin, Prediction of drug absorption using multivariate statistics, Journal of medicinal chemistry, 43 (2000) 3867-3877.
[75] I. Muegge, S.L. Heald, D. Brittelli, Simple selection criteria for drug-like chemical matter, Journal of medicinal chemistry, 44 (2001) 1841-1846.
[76] J.H. Lin, M. Yamazaki, Role of P-glycoprotein in pharmacokinetics, Clinical pharmacokinetics, 42 (2003) 59-98.
[77] L. Zanin, G. Saraceno, P.P. Panciani, G. Renisi, L. Signorini, K. Migliorati, M.M. Fontanella, SARS-CoV-2 can induce brain and spine demyelinating lesions, Acta Neurochirurgica, (2020) 1-4.
[78] E. Raschi, V. Vasina, E. Poluzzi, F. De Ponti, The hERG K+ channel: target and antitarget strategies in drug development, Pharmacological research, 57 (2008) 181-195.
[79] J.M. Kratz, U. Grienke, O. Scheel, S.A. Mann, J.M. Rollinger, Natural products modulating the hERG channel: heartaches and hope, Natural product reports, 34 (2017) 957-980.